MedTrace Logo

Efficacies of Two Bismuth Quadruple Therapies in the Second-line Treatment of H Pylori Infection

NCT03779087 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2023-10-26

No results posted yet for this study

Summary

From the profiles of antibiotic susceptibility data following eradication therapy, tetracycline, amoxicillin and levofloxacin are all good candidates of antibiotics used in the rescue treatment.

Conditions

  • Helicobacter Pylori Infection

Interventions

DRUG

10d TL quadruple therapy

esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, tetracycline 500 mg qid, levofloxacin 500 mg qd.

DRUG

10d AL quadruple therapy

esomeprazole 40 mg bid., tripotassium dicitrate bismuthate 300mg qid, amoxicillin 500 mg qid, levofloxacin 500 mg qd.

Sponsors & Collaborators

  • Ping-I (William) Hsu, M.D.

    lead OTHER

Principal Investigators

  • Ping-I Hsu, Bachelor · Kaohsiung Veterans General Hospital.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
90 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-11
Primary Completion
2020-06-30
Completion
2020-06-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03779087 on ClinicalTrials.gov